Physician profile
Wan Tu
NPI 1932762051
$3,229.68
in general payments reported to CMS, 2019-2025
13 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $433 · 2023: $1,308 · 2024: $1,120 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,797.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,053.24 | 2022-2025 | Linzess |
| Gilead Sciences, INC. | $708.73 | 2023-2025 | Vemlidy, Livdelzi |
| Astrazeneca Pharmaceuticals LP | $530.79 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $261.62 | 2023-2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.81 | 2022-2023 | Jardiance |
| Madrigal Pharmaceuticals | $150.00 | 2024 | Rezdiffra |
| Genzyme Corporation | $147.32 | 2023 | |
| Lilly USA, LLC | $64.32 | 2022-2023 | Jardiance, Mounjaro |
| Ibsa Pharma INC. | $57.38 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.91 | 2022 | |
| Glaxosmithkline, LLC. | $23.34 | 2022 | |
| Phadia US INC. | $21.06 | 2023 | Immunocap |
| Merck Sharp & Dohme LLC | $20.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wan Tu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.